Have a feature idea you'd love to see implemented?
Let us know!
CRIS Curis Inc
Price (delayed)
$4.1
Market cap
$34.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.78
Enterprise value
$17.12M
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of
Highlights
Curis's EPS has increased by 16% YoY and by 5% QoQ
The net income is up by 4.4% since the previous quarter and by 3.3% year-on-year
CRIS's debt is down by 8% from the previous quarter but it is up by 5% YoY
The equity has plunged by 130% YoY
CRIS's quick ratio has dropped by 79% year-on-year and by 33% since the previous quarter
Key stats
What are the main financial stats of CRIS
Market
Valuations
Earnings
Shares outstanding
8.47M
Market cap
$34.71M
Enterprise value
$17.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
Revenue
$10.26M
EBIT
-$45.48M
EBITDA
-$43.91M
Free cash flow
-$40.49M
Per share
Balance sheet
Liquidity
EPS
-$7.78
Free cash flow per share
-$6.82
Book value per share
-$1.46
Revenue per share
$1.73
TBVPS
$5.64
Total assets
$42.47M
Total liabilities
$51.21M
Debt
$3.26M
Equity
-$8.74M
Working capital
$4.9M
Debt to equity
-0.37
Current ratio
1.22
Quick ratio
1.08
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
-428%
Gross margin
98.7%
Net margin
-443.3%
Operating margin
-465.4%
Return on assets
-78.4%
Return on equity
-923.4%
Return on invested capital
-394.2%
Return on capital employed
-222.5%
Return on sales
-443.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRIS stock price
How has the Curis stock price performed over time
Intraday
10.81%
1 week
3.02%
1 month
-23.08%
1 year
-51.88%
YTD
-67.84%
QTD
-23.93%
Financial performance
How have Curis's revenue and profit performed over time
Revenue
$10.26M
Gross profit
$10.12M
Operating income
-$47.75M
Net income
-$45.48M
Gross margin
98.7%
Net margin
-443.3%
CRIS's net margin is up by 5% from the previous quarter and by 3.7% YoY
CRIS's operating margin is up by 4.6% since the previous quarter but it is down by 2.6% year-on-year
Curis's operating income has increased by 3.6% QoQ but it has decreased by 3% YoY
The net income is up by 4.4% since the previous quarter and by 3.3% year-on-year
Growth
What is Curis's growth rate over time
Valuation
What is Curis stock price valuation
P/E
N/A
P/B
N/A
P/S
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
Curis's EPS has increased by 16% YoY and by 5% QoQ
The equity has plunged by 130% YoY
CRIS's price to sales (P/S) is 89% lower than its 5-year quarterly average of 20.7 and 54% lower than its last 4 quarters average of 5.1
Efficiency
How efficient is Curis business performance
CRIS's return on equity has dropped by 182% since the previous quarter
The ROIC has plunged by 103% from the previous quarter
The company's return on assets has shrunk by 57% YoY and by 15% QoQ
Curis's return on sales has increased by 5% QoQ and by 3.7% YoY
Dividends
What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRIS.
Financial health
How did Curis financials performed over time
The company's total assets is 17% lower than its total liabilities
CRIS's quick ratio has dropped by 79% year-on-year and by 33% since the previous quarter
The current ratio has dropped by 77% year-on-year and by 31% since the previous quarter
CRIS's debt is 137% more than its equity
The equity has plunged by 130% YoY
The debt to equity has soared by 93% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.